Correction to Novartis Wins FDA Approval for Expanded Prostate Cancer Treatment Article on July 31
Dow Jones2026/08/03 21:37Novartis's Pluvicto was approved by the Food and Drug Administration for use in combination with an androgen receptor pathway inhibitor. "Novartis Wins FDA Approval for Expanded Prostate Cancer Treatment For Pluvicto," at 5:06 p.m. ET on July 31, incorrectly said Pluvicto was approved for use in combination with an androgen receptor pathway inhibitor and androgen deprivation therapy.
(END) Dow Jones Newswires
August 03, 2026 17:37 ET (21:37 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Volkswagen plunges! Profit forecast for 2026 significantly lowered, Porsche writes down €6 billion
Volkswagen expects the Group's operating sales return in 2026 to reach a maximum of only 1%, far below the previously projected 4% to 5.5%. The company anticipates that special items will impact full-year operating profit by about 10 billion euros, with around 6 billion euros attributable to non-cash impairments of goodwill in Porsche's operations. Increased competitiveness from Chinese automakers and accelerated consumer demand shift toward pure electric vehicles are also significant pressures facing Volkswagen. As a result of this news, Volkswagen's share price closed down 5.6% on Friday.
Glaukos Chief Development Officer Tomas Navratil sells 1,457 common shares worth $242,953.44
IT Tech Packaging auditor HCL resigns, company seeks replacement
As US Treasury yields rise, the cost of borrowing short-term Treasuries surges, with traders aggressively building short positions
The US Treasury will conduct auctions of two-year, five-year, and seven-year Treasury bonds next week. Currently, traders are racing to borrow bonds to short them, driving the borrowing costs for short-term Treasuries sharply higher. On Friday, the overnight repo rate for borrowing the current two-year Treasury was about 0.79%, while the rate for the five-year even dropped to as low as -0.85%. In contrast, the repo rate for regular Treasuries was around 3.88%.
Crypto prices
More
